Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
QurAlis
Biotech
Ovid eyes next chapter with CEO transition—Chutes & Ladders
Ovid's Levin set to become chairman as its next CEO stands ready. FDA’s oncology head takes top CDER post. Metagenomi shuffles CEO in reorg. Plus more.
Darren Incorvaia
,
Zoey Becker
Nov 14, 2025 8:30am
J&J, Bayer, Santa Ana, Regenxbio and more—Chutes & Ladders
Jun 14, 2024 8:30am
Lilly pays QurAlis $45M for preclinical ALS, dementia prospect
Jun 3, 2024 5:00am
QurAlis, Unlearn link to use machine learning in ALS research
Jun 28, 2023 11:30am
QurAlis nabs early ALS compounds from Eli Lilly
Jul 1, 2020 7:55am
QurAlis nabs $42M funding round for ALS, frontotemporal dementia
May 13, 2020 8:10am
